DRTS:NASDAQ, Alpha Tau Medical Ltd.
Why DRTS stock fell on November 16
Alpha Tau Medical Ltd. fell 10.5%
on Monday, November 16, 2026, on 2,286,815 shares, 3.9 times its average daily volume.
Headlines around the move:
DRTS stock overview
Alpha Tau Medical Ltd. (DRTS:NASDAQ) closed at $11.65 on November 20, 2026,
up 3.01% on the day.
The stock trades 26.2% below its 52-week high of $15.79
and 239.7% above its 52-week low of $3.43.
Over the past year, it gained 196.1%.
Alpha Tau Medical Ltd. is part of the Health Care sector.
Key figures
- Price
- $11.65
- Day change
- +3.01%
- Volume
- 353,669
- Average volume
- 591,873
- Market cap
- 1B+
- 52-week range
- $3.43 – $15.79
- 50-day average
- $13.84
- 200-day average
- $11.01
Price action over the past year
In 252 trading sessions since November 19, 2025, DRTS closed higher on 129 days (51%).
Its best day was May 11, 2026 (+21.50%) and its worst was May 4, 2026 (-11.83%).
The stock moved 10% or more in a single session 15 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
DRTS news
-
Nov 19, 2026:
Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update
-
Nov 18, 2026:
How Investors May Respond To Alpha Tau Medical Stock After Glioblastoma Trial Results
-
Nov 16, 2026:
Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients
-
Nov 15, 2026:
Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16
-
Nov 13, 2026:
Buy Alert: 5 Stocks Analysts Upgraded on Wednesday
-
Nov 12, 2026:
Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
-
Nov 11, 2026:
Nvidia downgraded, Mercury Systems upgraded: Wall Street's top analyst calls
-
Nov 7, 2026:
Alpha Tau Medical (DRTS) Stock May Be Hard To Justify Despite Its 343% Run
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors.
Similar stocks
Find more stocks like DRTS with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.